Royal Bank Of Canada Gracell Biotechnologies Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.43 - $10.04 $60,750 - $250,999	25,000 Added 83333.33%	25,030 $251,000
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $123 - $515	-85 Reduced 73.91%	30 $0
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $126 - $175	70 Added 155.56%	115 $0
Q4 2022 Feb 14, 2023	SELL	$2.08 - $3.96 $128 - $245	-62 Reduced 57.94%	45 $0
Q3 2022 Nov 14, 2022	SELL	$2.08 - $5.15 $3,105 - $7,688	-1,493 Reduced 93.31%	107 $0
Q2 2022 Aug 15, 2022	BUY	$1.95 - $5.5 $3,120 - $8,800	1,600 New	1,600 $9,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.